Renalytix plc
("Renalytix" or the
"Company")
Confirmation of "Foreign Private Issuer"
re-qualification
LONDON and NEW
YORK, 17
January 2025 -
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is
commercialising the only FDA-approved and Medicare reimbursed
prognostic test to support early-stage risk assessment for chronic
kidney disease, confirms that it has re-qualified for
Foreign Private Issuer ("FPI") status.
Following the decision to move the listing of
the Company's American Depository Shares ("ADSs") from Nasdaq to
the OTC Markets Group Inc., the ADSs began trading on OTCQB
Venture Market under the symbol "RNLXY" on 8 October 2024. The
Company anticipates that transferring
trading to OTCQB and the re-acquisition of FPI status will provide
associated cost savings of up to £1.9 million p.a.
In addition, following
re-qualification as an FPI the Company is
no longer required to file periodic reports on a quarterly basis.
The Company will continue to update shareholders with period end
trading updates and financial results for the six month period
ending 31 December and fiscal year ending 30 June.
For further information,
please contact:
|
Renalytix plc
|
www.renalytix.com
|
|
James McCullough, CEO
|
Via
Walbrook PR
|
|
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020
7710 7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Oberon Capital
(Joint Broker)
|
Tel: 020
3179 5300
|
|
Mike Seabrook / Nick Lovering
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 /
07407 804 654
|
|
|
|
|
CapComm Partners
|
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About
Renalytix (www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an
artificial intelligence-enabled in vitro diagnostics company, focused
on optimizing clinical management of kidney disease to drive
improved patient outcomes. Renalytix has received FDA approval and
Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.
Unrecognized and uncontrolled kidney disease
remains one of the largest barriers to controlling cost and
suffering in the United States and the United Kingdom's medical
system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical
validation, kidneyintelX.dkd is the only
FDA-approved and Medicare reimbursed prognostic tool capable of
understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed
across large physician group practices and health systems in select
regions of the United States.
The over 10,000 patients that have been tested
by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In
patient populations where kidneyintelX.dkd has been deployed, a
demonstrated and significant increase in diagnosis, prognosis, and
treatment rates have been recorded. kidneyintelX.dkd now has full
reimbursement established by Medicare, the largest insurance payer
in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended
for use in the international chronic kidney disease clinical
guidelines (KDIGO).
